News

November 8, 2022
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in fireside chats at three
Additional Formats
November 2, 2022
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA ® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUNTAIN VIEW, Calif. and LAUSANNE, Switzerland , Nov.
Additional Formats
September 6, 2022
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in three upcoming investor
Additional Formats
June 1, 2022
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif. , June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at the 2022
Additional Formats
Displaying 1 - 10 of 19